Literature DB >> 18094369

Evaluation of 1p36 markers and clinical outcome in a skull base chordoma study.

Mauro Longoni1, Francesca Orzan, Michela Stroppi, Nicola Boari, Pietro Mortini, Paola Riva.   

Abstract

Chordomas are rare embryogenetic tumors, arising from remnants of the notochord, characterized by local invasiveness and variable tendency for recurrence. No molecular markers are currently used in a clinical setting to distinguish chordomas with an indolent or an aggressive pattern. Among the genetic lesions observed in this tumor, one of the most commonly detected is 1p loss. In a previous study we observed 1p36 loss of heterozygosity (LOH) in 85% of the analyzed chordomas. We studied a group of 16 homogeneously treated skull base chordomas (SBCs), reporting 1p36 LOH in 75% of them and determining the expression pattern of eight apoptotic genes mapped at 1p36. No tumors shared a common expression profile with nucleus pulposus, which is considered the only adult normal tissue deriving from notochord. In particular, tumor necrosis factor receptor superfamily genes TNFRSF8, TNFRSF9, and TNFRSF14 were differently expressed compared with control in a higher percentage of tumors (40%-53%) than were the remaining analyzed genes, suggesting that the deregulation of these three genes might have a role in chordoma tumorigenesis. The presence/absence of LOH and the expression/nonexpression of each apoptotic gene were studied in a survival analysis. Our results suggest that the lack of 1p36 LOH or the presence of TNFRSF8 expression might be associated with a better prognosis in patients with SBCs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18094369      PMCID: PMC2600838          DOI: 10.1215/15228517-2007-048

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  41 in total

1.  A multidisciplinary team approach to skull base chordomas.

Authors:  H A Crockard; T Steel; N Plowman; A Singh; J Crossman; T Revesz; J L Holton; A Cheeseman
Journal:  J Neurosurg       Date:  2001-08       Impact factor: 5.115

2.  Expression of growth factors and structural proteins in chordomas: basic fibroblast growth factor, transforming growth factor alpha, and fibronectin are correlated with recurrence.

Authors:  M Levent Deniz; Türker Kiliç; Idil Almaata; Ozlem Kurtkaya; Aydin Sav; M Necmettin Pamir
Journal:  Neurosurgery       Date:  2002-09       Impact factor: 4.654

3.  Chromosome 1p and 11q deletions and outcome in neuroblastoma.

Authors:  Edward F Attiyeh; Wendy B London; Yael P Mossé; Qun Wang; Cynthia Winter; Deepa Khazi; Patrick W McGrady; Robert C Seeger; A Thomas Look; Hiroyuki Shimada; Garrett M Brodeur; Susan L Cohn; Katherine K Matthay; John M Maris
Journal:  N Engl J Med       Date:  2005-11-24       Impact factor: 91.245

4.  Prognostic factors in chordoma: role of postoperative radiotherapy.

Authors:  C Thieblemont; P Biron; F Rocher; D Bouhour; J Y Bobin; J P Gérard; J Y Blay
Journal:  Eur J Cancer       Date:  1995-12       Impact factor: 9.162

5.  Prognostic value of MIB-1, E-cadherin, and CD44 in pediatric chordomas.

Authors:  Aly G Saad; Margaret H Collins
Journal:  Pediatr Dev Pathol       Date:  2005-07-14

6.  Histological study on local invasiveness of clival chordoma. Case report of autopsy.

Authors:  S Oikawa; K Kyoshima; T Goto; T Iwashita; T Takizawa; S Kobayashi; M Ito
Journal:  Acta Neurochir (Wien)       Date:  2001-10       Impact factor: 2.216

7.  Cadherins and catenins in clival chordomas: correlation of expression with tumor aggressiveness.

Authors:  Aymara Triana; Chandranath Sen; David Wolfe; Rachel Hazan
Journal:  Am J Surg Pathol       Date:  2005-11       Impact factor: 6.394

8.  Alterations of G1-S checkpoint in chordoma: the prognostic impact of p53 overexpression.

Authors:  Takahiko Naka; Carsten Boltze; Doerthe Kuester; Torss-Oliver Schulz; Regine Schneider-Stock; Angela Kellner; Amir Samii; Christian Herold; Helmut Ostertag; Albert Roessner
Journal:  Cancer       Date:  2005-09-15       Impact factor: 6.860

9.  Imatinib mesylate in chordoma.

Authors:  Paolo G Casali; Antonella Messina; Silvia Stacchiotti; Elena Tamborini; Flavio Crippa; Alessandro Gronchi; Rosaria Orlandi; Carla Ripamonti; Carlo Spreafico; Raffaello Bertieri; Rossella Bertulli; Maurizio Colecchia; Elena Fumagalli; Angela Greco; Federica Grosso; Patrizia Olmi; Marco A Pierotti; Silvana Pilotti
Journal:  Cancer       Date:  2004-11-01       Impact factor: 6.860

10.  Chordomas and chondrosarcomas of the cranial base: results and follow-up of 60 patients.

Authors:  E Gay; L N Sekhar; E Rubinstein; D C Wright; C Sen; I P Janecka; C H Snyderman
Journal:  Neurosurgery       Date:  1995-05       Impact factor: 4.654

View more
  14 in total

1.  Chordoma: an update on the pathophysiology and molecular mechanisms.

Authors:  Xin Sun; Francis Hornicek; Joseph H Schwab
Journal:  Curr Rev Musculoskelet Med       Date:  2015-12

2.  The prognostic value of Ki-67, p53, epidermal growth factor receptor, 1p36, 9p21, 10q23, and 17p13 in skull base chordomas.

Authors:  Craig Horbinski; Gerard J Oakley; Kathleen Cieply; Geeta S Mantha; Marina N Nikiforova; Sanja Dacic; Raja R Seethala
Journal:  Arch Pathol Lab Med       Date:  2010-08       Impact factor: 5.534

3.  High-resolution whole-genome analysis of skull base chordomas implicates FHIT loss in chordoma pathogenesis.

Authors:  Roberto Jose Diaz; Mustafa Guduk; Rocco Romagnuolo; Christian A Smith; Paul Northcott; David Shih; Fitim Berisha; Adrienne Flanagan; David G Munoz; Michael D Cusimano; M Necmettin Pamir; James T Rutka
Journal:  Neoplasia       Date:  2012-09       Impact factor: 5.715

Review 4.  Systemic therapy options for unresectable and metastatic chordomas.

Authors:  Silvia Stacchiotti; Paolo Giovanni Casali
Journal:  Curr Oncol Rep       Date:  2011-08       Impact factor: 5.075

Review 5.  The biological basis for modern treatment of chordoma.

Authors:  Roberto Jose Diaz; Michael D Cusimano
Journal:  J Neurooncol       Date:  2011-03-08       Impact factor: 4.130

Review 6.  Epigenetic deregulations in chordoma.

Authors:  Xin Yu; Zheng Li
Journal:  Cell Prolif       Date:  2015-08-10       Impact factor: 6.831

7.  Molecular genetic study of novel biomarkers for early diagnosis of oral squamous cell carcinoma.

Authors:  Kim Yong-Deok; Jeon Eun-Hyoung; Kim Yeon-Sun; Pang Kang-Mi; Lee Jin-Yong; Cho Sung-Hwan; Kim Tae-Yun; Park Tae-Sung; Kim Soung-Min; Kim Myung-Jin; Lee Jong-Ho
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2015-03-01

8.  Genomic and transcriptomic characterization of skull base chordoma.

Authors:  Jason K Sa; In-Hee Lee; Sang Duk Hong; Doo-Sik Kong; Do-Hyun Nam
Journal:  Oncotarget       Date:  2017-01-03

9.  FAS/FASL are dysregulated in chordoma and their loss-of-function impairs zebrafish notochord formation.

Authors:  Luca Ferrari; Anna Pistocchi; Laura Libera; Nicola Boari; Pietro Mortini; Gianfranco Bellipanni; Antonio Giordano; Franco Cotelli; Paola Riva
Journal:  Oncotarget       Date:  2014-07-30

Review 10.  Immunophenotypic features of dedifferentiated skull base chordoma: An insight into the intratumoural heterogeneity.

Authors:  Kelvin Manuel Piña Batista; Kenia Yoelvi Alvarez Reyes; Fátima Pérez Lopez; Andrés Coca Pelaz; Ivan Fernandez Vega; José Luis Llorente Pendás; Antonio Saiz Ayala; Aurora Astudillo; Jorge Andrés Nuñez Rojas; Patricia Barrio Fernandez
Journal:  Contemp Oncol (Pozn)       Date:  2017-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.